Abstract:Combating influenza is one of the perennial global public health issues to be managed. Antiviral drugs are useful for the treatment of influenza in the absence of an appropriate vaccine. However, the appearance of resistant strains necessitates a constant search for new drugs. In this study, we investigated novel anti-influenza drug candidates using in vitro and in vivo assays. We identified anti-influenza hit compounds using a high-throughput screening method with a green fluorescent protein-tagged recombinant influenza virus. Through subsequent analyses of their cytotoxicity and pharmacokinetic properties, one candidate (IY7640) was selected for further evaluation. In a replication kinetics analysis, IY7640 showed greater inhibitory effects during the early phase of viral infection than the viral neuraminidase inhibitor oseltamivir. In addition, we observed that hemagglutinin (HA)-mediated membrane fusion was inhibited by IY7640 treatment, indicating that the HA stalk region, which is highly conserved across various (sub)types of influenza viruses, may be the molecular target of IY7640. In an escape mutant analysis in cells, amino acid mutations were identified at the HA stalk region of the 2009 pandemic H1N1 (pH1N1) virus. Even though the in vivo efficacy of IY7640 did not reach complete protection in a lethal challenge study in mice, these results suggest that IY7640 has potential to be developed as a new type of anti-influenza drug.IMPORTANCE Anti-influenza drugs with broad-spectrum efficacy against antigenically diverse influenza viruses can be highly useful when no vaccines are available. To develop new anti-influenza drugs, we screened a number of small molecules and identified a strong candidate, IY7640. When added at the time of or after influenza virus infection, IY7640 was observed to successfully inhibit or reduce viral replication in cells. We subsequently discovered that IY7640 targets the stalk region of the influenza HA protein, which exhibits a relatively high degree of amino acid sequence conservation across various (sub)types of influenza viruses. Furthermore, IY7640 was observed to block HA-mediated membrane fusion of H1N1, H3N2, and influenza B viruses in cells. Although it appears less effective against strains other than H1N1 subtype viruses in a challenge study in mice, we suggest that the small molecule IY7640 has potential to be optimized as a new anti-influenza drug.

Delivery System Targeting Hemagglutinin of Influenza Virus A to Facilitate Antisense-Based Anti-H1N1 Therapy.

In Vitro and in Vivo Protection Against the Highly Pathogenic H5N1 Influenza Virus by an Antisense Phosphorothioate Oligonucleotide

Targeted recruitment of immune effector cells for rapid eradication of influenza virus infections

Novel Small Molecule Targeting the Hemagglutinin Stalk of Influenza Viruses

Potent sialic acid inhibitors that target influenza A virus hemagglutinin

In vivo inhibition of influenza A virus replication by RNA interference targeting the PB2 subunit via intratracheal delivery

A Dna Aptamer Against Influenza A Virus: an Effective Inhibitor to the Hemagglutinin-Glycan Interactions

Design, Synthesis, and Biological Evaluation of Novel Penindolone Derivatives As Potential Inhibitors of Hemagglutinin-Mediated Membrane Fusion.

Polycation-mediated delivery of siRNAs for prophylaxis and treatment of influenza virus infection.

Inhibition of Highly Pathogenic Avian H5N1 Influenza Virus Replication by RNA Oligonucleotides Targeting NS1 Gene.

A small molecule compound targeting hemagglutinin inhibits influenza A virus and exhibits broad-spectrum antiviral activity

Identification of a Small-Molecule Inhibitor of Influenza Virus Via Disrupting the Subunits Interaction of the Viral Polymerase.

Inhibition of influenza A virus replication by RNA interference targeted against the PB1 subunit of the RNA polymerase gene

Proteomic Analysis at the Subcellular Level for Host Targets Against Influenza A Virus (H1N1)

Inhibition of Highly Pathogenic Avian H5n1 Influenza Virus Propagation by Rna Oligonucleotides Targeting the Pb2 Gene in Combination with Celecoxib

Effective Small Interfering RNAs Targeting Matrix and Nucleocapsid Protein Gene Inhibit Influenza A Virus Replication in Cells and Mice

A Novel Natural Influenza A H1n1 Virus Neuraminidase Inhibitory Peptide Derived From Cod Skin Hydrolysates And Its Antiviral Mechanism

Design, Synthesis and Biological Evaluation of Amino Acids-Oleanolic Acid Conjugates As Influenza Virus Inhibitors.

Covalent Organic Framework-Based Theranostic Platforms for Restricting H1N1 Influenza Virus Infection

Multivalent peptide dendrimers inhibit the fusion of viral-cellular membranes and the cellular NF-κB signaling pathway

Discovery and Characterization of a Novel Peptide Inhibitor Against Influenza Neuraminidase